In a phase I/II trial (NCT03037385), selective RET inhibitor pralsetinib demonstrated broad antitumor activity in RET fusion-positive solid tumors excluding thyroid and non-small cell lung cancers. The gene discussed is RET; the disease is non-small cell lung carcinoma.